Multiple myeloma (MM) is a disease with known immune dysregulation. Natural killer (NK) cells have shown preclinical activity in MM. We conducted a first-in-human study of umbilical cord blood-derived (CB) NK cells for MM patients undergoing high dose chemotherapy and autologous haematopoietic stem cell transplantation (auto-HCT). Patients received lenalidomide (10 mg) on days À8 to À2, melphalan 200 mg/m 2 on day À7, CB-NK cells on day À5 and auto-HCT on day 0. Twelve patients were enrolled, three on each of four CB-NK cell dose levels: 5 9 10 6 , 1 9 10 7 , 5 9 10 7 and 1 9 10 8 CB-NK cells/kg. Ten patients had either high-risk chromosomal changes or a history of relapsed/progressed disease. There were no infusional toxicities and no graft-versus-host disease. One patient failed to engraft due to poor autologous graft quality and was rescued with a back-up autologous graft. Overall, 10 patients achieved at least a very good partial response as their best response, including eight with near complete response or better. With a median follow-up of 21 months, four patients have progressed or relapsed, two of whom have died. CB-NK cells were detected in vivo in six patients, with an activated phenotype (NKG2D + /NKp30 + ). These data warrant further development of this novel cellular therapy.
Multiple myeloma (MM) is the second most common haematological malignancy in adults and, despite many recent advances in therapy (Alexanian et al, 2014) remains incurable (Laubach et al, 2016) . MM is a disease characterized by immune dysregulation, whereby a suppressed immune system can allow for unchecked plasma cell proliferation (Rossi et al, 2013) and the malignant plasma cells can themselves further suppress the immune system (Brown et al, 2001; Ratta et al, 2002; Frassanito et al, 2015) . Long-term remission with allogeneic haematopoietic stem cell transplantation (HCT) for some patients suggests the possibility of an allogeneic graft-versus-myeloma effect (Cavo et al, 2000; Giaccone et al, 2015) . However, the morbidity and mortality associated with allotransplantation for MM has limited its application.
Natural killer (NK) cells are part of the innate immune system and have been implicated in tumour immunity and defence (Guillerey & Smyth, 2015) . Importantly, NK cells do not require prior exposure or sensitization to kill a specific target. While the exact mechanism of NK cells anti-tumour immunity is not known, a complex interplay between activating and inhibitory receptors probably determines cytotoxicity against a specific target (Long et al, 2013) . This includes possible dis-inhibition of the killer immunoglobulin like receptor (KIR) due to absence of human leucocyte antigen (HLA) class I molecules on target cells ('missing self hypothesis') as well as death receptor-induced apoptosis via Fas ligand and tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) (Zamai et al, 1998) .
The anti-MM effect of NK cells was first described by Frohn et al (2002) . Since then, we and others have corroborated these findings, demonstrating that NK cells are cytotoxic against MM cells in vitro and in vivo (Frohn et al, 2002; Garg et al, 2012; Shah et al, 2013) . Unfortunately, autologous NK cells from patients with MM appear to be dysfunctional. These NK cells can have an unfavourable balance between activating and inhibitory receptors (Fauriat et al, 2006; Costello et al, 2013) and can be inhibited by the products of plasma cells (Gherman et al, 1987) and the hypoxic bone marrow microenvironment itself (Sarkar et al, 2013) . Furthermore possible protection by class I expression (Carbone et al, 2005; Gao et al, 2014) in some patients suggests that any successful activity against MM requires highly active NK cells, ideally from an allogeneic source. While immunomodulatory drugs, such as lenalidomide, may augment NK cell function (Zhu et al, 2008; Lagrue et al, 2015) clinical experience suggests that this may not be sufficient to thwart disease progression. Because of these limitations of autologous NK cell function, we have been interested in the application of allogeneic NK cells as an adoptive cellular therapy to treat MM.
The clinical safety of peripheral blood-derived allogeneic NK cell infusion in MM patients has been demonstrated (Shi et al, 2008; Szmania et al, 2015) . This requires collection of peripheral blood from a normal donor, which can be logistically cumbersome. To minimize these obstacles we have been interested in NK cells derived from cryopreserved umbilical cord blood (CB), a known source of haematopoietic progenitor cells (Robin et al, 2015) . Our group has previously published a Good Manufacturing Practice (GMP)-compliant method of NK cell expansion from thawed CB mononuclear cells. This method yields a >1000-fold expansion of NK cells which demonstrate anti-MM activity in vitro and in vivo (Shah et al, 2013) . Based on these findings we launched a first-in-human study of CB-NK cells for patients with MM who are receiving high-dose chemotherapy and autologous HCT.
Our data demonstrate that CB-NK cells in doses up to 1 9 10 8 cells/kg can be reliably produced for clinical use.
Furthermore, these CB-NK cells are well tolerated in the setting of high dose chemotherapy and autologous-HCT. In addition, our correlative analyses suggest that CB-NK cells maintain an active phenotype in vivo, after adoptive transfer. These results provide a platform for further development of this novel cellular therapy.
Methods

Patients
All research was approved by the M.D. Anderson Cancer Center Institutional Review Board and all subjects gave written informed consent. This study was registered at clinicaltrials.gov (NCT01729091). Patients with symptomatic MM, aged 18-75 years with adequate cardiac, hepatic, renal and pulmonary function were eligible ( Fig S1 ). An available umbilical cord blood unit matched at 4/6 HLA loci (HLA-A, -B, -DR) was also required. When possible, CB units with potential NK alloreactivity were chosen (Ruggeri et al, 1999) . Specifically, for patients whose HLA typing included two HLA-C alleles belonging to the same group (C1 or C2 homozygous) we attempted to choose a CB unit with the opposite C allele group or a unit that was heterozygous for the C1 or C2 alleles. For patients who had two HLA-B alleles that did not belong to the Bw4 group, we attempted to select a Bw4 positive CB unit. As an allogeneic NK cell infusion was planned in the setting of autologous peripheral blood progenitor cell (PBPC) transplantation after myeloablative chemotherapy, patients were required to have at least 6 9 10 6 CD34 + cells/kg available for haematopoietic rescue.
This would allow for a PBPC dose of 4 9 10 6 CD34 + cells/ kg for the primary autograft and a back-up PBPC dose of 2 9 10 6 CD34 + cells/kg in the case of NK cell-mediated graft failure. Due to the inclusion of lenalidomide in the preparative regimen, patients were also registered in the accompanying REMS â program (Celgene Corp, Summit, NJ, USA).
Patients who were receiving other investigational agents or had ongoing illness (aside from MM), a history of hypersensitivity to lenalidomide or thalidomide or human immunodeficiency virus positivity were excluded from the study.
CB-NK cell production and release criteria
Cord blood units were obtained from the MD Anderson Cord Blood Bank (Houston, TX, USA) under an Institutional Review Board-approved protocol. The method for NK cell expansion from CB units has previously been published (Shah et al, 2013 
Treatment
The treatment schema is outlined in Fig 1. Due to pre-clinical data demonstrating synergy between lenalidomide and NK cells (Acebes-Huerta et al, 2014; Lagrue et al, 2015) and safety of the combination of high dose melphalan with lenalidomide , patients received lenalidomide (10 mg orally daily) from days À8 to À2. Melphalan 200 mg/m 2 was given intravenously on day À7. The freshly expanded CB-NK cells were infused on day À5. We hypothesized that this would allow for minimal interference of melphalan with the CB-NK cell product and allow for CB-NK cells to treat any remaining disease present after melphalan treatment. Autologous PBPC were infused on day 0. Correlative analyses were performed on day À4, day 0 and weekly thereafter for up to 4 weeks.
Trial design
This was a phase I, single-centre, dose escalation study of CB-NK cells for patients with MM. The primary objective was to determine the maximum tolerated dose (MTD) of CB-NK cells in combination with high dose melphalan and low dose lenalidomide. Four doses of CB-NK cells were tested: 5 9 10 6 , 1 9 10 7 , 5 9 10 7 and 1 9 10 8 CB-NK cells/ kg. Patients were enrolled in cohorts of 3 per dose level. To ensure safety, a 42-day waiting period and full review by the Investigational New Drug (IND) office was required between the infusion of NK cells for the last patient on a dose level and enrolment on the next dose level. Dose-limiting toxicities (DLT) were defined as grade 4 CB-NK cell infusionrelated toxicity, failure to engraft (defined as absolute neutrophil count of 0Á5 9 10 9 /l for 3 consecutive days) by day (+28), grade 3-5 allergic reaction related to CB-NK cell infusion, grade 3-5 organ toxicity within 30 days of CB-NK infusion, grade 3-4 graft-versus-host disease (GVHD) or any treatment-related death within 8 weeks of CB-NK cell infusion. 
Correlative analyses
The secondary objective was to determine persistence of donor-derived CB-NK cells in the recipient. To do this, we collected serial PB samples at day À4, day 0 (before infusion of PBPC), day 7 and weekly thereafter until negative results were obtained. We applied our institution's standard DNA microsatellite chimerism assay (De Lima et al, 2002) to detect donor CB-NK cells. Briefly, polymerase chain reaction (PCR)-based microsatellite polymorphism analysis was performed using capillary electrophoresis (CE-PCR) on DNA from the pre-transplant, CB donor and post-transplant PB samples. DNA from sorted T-lymphocytes (T-cells), myeloid cell (M-cells) and/or NK-cells was also used in addition to the total DNA as applicable. A total of eight microsatellite regions (D6S264, D3S1282, D18S62, D3S1300, DM1, AR, D11S987 and D9S171) were assessed in each specimen to identify the most distinct or discriminating (informative) marker/s between CB donor and recipient DNA. The area under the curve for the informative marker was used to calculate the per cent engraftment using the formula: % engraftment = 100 9 [Donor/(Donor + Recipient)] DNA in posttransplant sample. The lower limit of detection for this assay was established to be 1%.
In parallel, we performed multiparameter flow cytometry to analyze the source (patient or CB) and the phenotype of circulating NK cells. Briefly, PB MNCs were subjected to Ficoll-separation. Thereafter, cells were stained for the following: CD56, CD3, CD16, PAN KIR, NKG2D, NKG2A, NKp30, NK p44, NKp46 and NKG2C. When possible, a 'flow chimerism' assay was performed: fluorochrome-conjugated antibodies against HLA groups Bw4 or Bw6 were applied to determine origin (donor CB unit versus recipient) of NK cells.
Results
Patients
A total of 12 patients were enrolled, with three patients per dose cohort. Table I summarizes the patients' disease characteristics and risk factors. Three patients had abnormal cytogenetics or fluorescence in situ hybridization (FISH) changes generally accepted as high risk (Avet-Loiseau et al, 2012) . Seven patients had a history of relapsed or progressive disease and three patients had received a prior autologous HCT. Patients had received a median of two lines of prior therapy (range 1-6).
CB-NK cell product
Expansion of CB-NK cells to target dose was reached in all 12 patients with a mean NK cell purity of 98Á9% (96Á8- 99Á7%) and were able to assess the functionality of these cells in a subset of patients (6/12). Consistent with our pre-clinical data, the NK cells were highly functional with CD107a degranulation in response to the K562 cell line as well as in vitro cytotoxicity against K562 and MM cell lines (Fig 2A,  B) . All CB-NK cell products met the release criteria mentioned above.
Toxicities
There were no toxicities with infusion of CB-NK cells. There were no cases of GVHD. Eleven of 12 patients engrafted at a median time of 10 days (9-12). One patient at dose level 4 (1 9 10 8 CB-NK cells/kg) failed to engraft.
Further examination of reference vials from this patient's PBPC product (collected several years prior at an outside institution) revealed poor viability (16-34% by 7-Aminoactinomycin D staining) of the cells. This patient received a back-up autologous PBPC product (2Á37 9 10 6 CD34 + cells/kg) that had been collected on a different day and exhibited greater CD34 viability. The patient then engrafted 10 days later.
Clinical outcomes
Overall, 10 patients achieved a very good partial response (VGPR) or better as a best response. Eight patients achieved a near complete response (CR) or better (Table II) . Six patients achieved MRD negativity by bone marrow flow cytometry. In comparison to responses going into the autologous HCT, seven patients were able to upgrade their response by day 90. All patients went on to receive lenalidomide-or bortezomib-based maintenance therapy. With a median follow-up of 21 months, four patients have progressed or relapsed with two of those four patients expiring due to progression.
Correlative analyses
To determine the persistence of the CB-derived NK cells, chimerism studies were performed. By microsatellite chimerism assay, donor-derived CB-NK cells were detected in 2/3 patients treated at dose level 3 (5 9 10 7 CB-NK cells/kg) and all three patients treated at dose level 4 (1 9 10 8 CB-NK cells/kg). The duration of CB-NK cell detection in these groups ranged from 5 to 12 days after CB-NK infusion (Table III) . Of note, while at least two patients seemed to increase their donor NK chimerism from day À1 to day 0, the corresponding decrease in peripheral blood leucocyte count suggests that this increase was most likely a relative versus an absolute in vivo expansion. In 4 of 12 patients the donor CB unit differed from the patient with regards to alleles in the Bw4 or Bw6 group. The flow chimerism assay was thus feasible in those patients, as shown in a representative sample presented in Fig 3. In each of these cases donor CB-NK cells were detected and persisted for up to 5 days (two patients), 12 days (one patient) or 26 days (one patient) after infusion. One of these patients (whose donor CB-NK persisted 12 days from infusion) had been treated on dose level 2 with 1 9 10 7 CB-NK cells/kg. This patient did not demonstrate CB-NK detection by our traditional DNA microsatellite chimerism assay, suggesting that the flow chimerism assay is more sensitive. 
NK, natural killer cell; PCR, polymerase chain reaction; WBC, white blood cell. *Collected on day (À1). †Collected on day (+1). To further characterize the in vivo phenotype of donor CB-NK cells, multicolour flow cytometry was performed. These data demonstrated that the adoptively transferred CB-NK cells expressed CD16, PAN KIR, NKG2D, NKG2A and NKp30. As seen in Fig 3C, donor CB-NK cells maintained expression of NKG2D in vivo. Additionally, the expression of activating receptors CD16 and NKp30 was generally higher in donor CB-NK cells versus endogenous NK cells. However, donor CB-NK cells appeared to express more NKG2A versus recipient NK cells. Expression of activating receptors NKp46 and NKG2D appeared to be similar between the two NK populations.
Discussion
While there have recently been a number of innovative strategies for the treatment of MM, the cure for this malignancy remains elusive. Our experience with allogeneic HCT, immunomodulatory agents and, more recently, antibody therapy (Lokhorst et al, 2015; Lonial et al, 2015) , suggests that immunotherapy is probably a necessary weapon in the fight against this disease. Furthermore, the interaction between the permissive immune system and the aggressive plasma cell indicates that exogenous immunotherapy is probably needed.
In this study we demonstrate, for the first time, the safety and feasibility of allogeneic NK cells derived from umbilical cord blood and their potential role in myeloma immunotherapy. For all 12 patients enrolled on this trial we were able to reliably expand NK cells from CB units in our GMP laboratory to reach our planned maximal dose of 1 9 10 8 CB-NK cells/kg. Of note, the product at time of infusion mirrored the activated phenotype demonstrated in our pre-clinical data (Shah et al, 2013) . While there was no dose-related toxicity associated with the CB-NK cell infusions, cost and logistics dictated that we cap the dose as above. Though we did not expand the entire CB unit maximally, we estimate that, with expansion of the full CB unit, we could have produced another log-fold of CB-NK cells for each patient, even those at the highest dose level (up to 1 9 10 9 CB-NK cells/kg).
From a clinical perspective, the CB-NK cells were well tolerated and there were no cases of GVHD. Though one patient did not initially engraft, this was attributed to the poor viability in the primary PBPC autograft and not the CB-NK cells. This was a relatively high-risk group of MM patients and clinical outcomes were similar to a comparable patient population at our centre (Kazmi et al, 2015; Shah et al, 2015) . However, we hesitate to make any conclusions about the clinical efficacy of these CB-NK cells, as we are limited by the small number of patients in this study and the subsequent administration of maintenance therapy (Table II) .
Our correlative data demonstrate that the adoptively transferred CB-NK cells are detectable in recipients for up to 26 days. While a DNA microsatellite chimerism assay was able to detect these cells at the 5 9 10 7 /kg dose, the flow chimerism assay increased our sensitivity and allowed for detection at one dose level below. Analysis of this data revealed that the CB-NK cells do maintain an active phenotype in vivo, with strong expression of NKG2D. Of note, this receptor has been implicated in the successful killing of MM by NK cells (El-Sherbiny et al, 2007; Martin-Antonio et al, 2015) . Though small patient numbers prevented quantitative comparisons between donor and recipient-derived NK cells, some qualitative suggestions could be made. We noted that there was expression of the inhibitory receptor NKG2A on the adoptively transferred CB-NK cells; this may suggest a role for combination therapy with recently developed NKG2A blocking antibodies. The phenotype data in our study are similar to those of a previous study with adoptively transferred PB-NK cells (Szmania et al, 2015) . We were not, however, able to demonstrate significant in vivo expansion or prolonged persistence, probably due to the absence of interleukin 2 (IL-2) administration and subsequent rejection by autologous lymphocytes. The use of systemic IL-2 to enhance donor NK cell persistence, as practiced by several groups (Miller et al, 2005; Szmania et al, 2015) , was omitted from our protocol to eliminate the possible induction of a regulatory T cell response, also reported with systemic IL-2 (Kennedy-Nasser et al, 2014; Liu et al, 2015) .
There remain several unanswered questions: while we were able to choose CB units with optimal KIR-HLA I alloreactivity in 7 of the 12 patients, we did not have such units in our CB bank for all patients. Thus we cannot yet determine what role, if any, KIR-HLA mismatch plays in this therapy. In addition, the lack of CB-NK cell persistence remains an issue. While donor CB-NK cells were detected after infusion, there was no long-term persistence (in the peripheral blood) and it is unclear whether the duration of persistence would correlate with clinical outcome. Furthermore, the short duration of the donor CB-NK cells makes it difficult to draw conclusions on the potential for GVHD of more persistent allogeneic NK cells. Finally, while lenalidomide has been shown in the pre-clinical setting to increase NK cell proliferation and function (Hernandez-Ilizaliturri et al, 2005) it is not clear if this has been successfully translated to our in vivo setting.
Based on our findings a phase II study of this therapy is currently in progress (NCT01729091). This trial will employ the same schema, at the dose of 1 9 10 8 CB-NK cells/kg, and will be powered to determine efficacy of this regimen. Based on our experience with our correlative studies, we will also apply a more comprehensive flow cytometry panel to examine additional markers of in vivo activation and exhaustion of adoptively transferred CB-NK cells. Future directions include administering multiple doses of CB-NK cells, genetic modification of the NK cells to improve specificity and persistence and combining CB-NK cells with antibody therapy. This last option is particularly intriguing, as the CB-NK cells strongly expressed CD16 in vivo and thus would be ideally 
